蔚蓝生物：公司业务以国内市场为主，国内业务收入占比约为92%

Core Viewpoint - The company, Weilan Bio (603739), primarily focuses on the domestic market, with approximately 92% of its revenue coming from domestic operations [1] Group 1: Domestic and International Market Focus - The company's business is mainly concentrated in the domestic market, with a revenue share of about 92% from domestic operations [1] - The overseas markets include the United States, European Union, Philippines, Egypt, and Brazil, but the revenue from these markets is relatively low [1] - Sales to the EU market are primarily conducted by domestic entities directly selling to EU customers, contributing a minor portion to overall revenue [1] Group 2: Compliance and Disclosure - The company commits to adhering to the Shanghai Stock Exchange's listing rules and will fulfill its information disclosure obligations in a timely manner [1] - Relevant information will be disclosed on the Shanghai Stock Exchange's website, ensuring transparency for investors [1]